Worldwide Clinical Trials announced the acquisition of UK‑based Catalyst Clinical Research to deepen early‑phase oncology capabilities and add functional service provider (FSP) offerings. The deal brings Catalyst’s specialized cancer expertise and FSP model into Worldwide’s portfolio and marks Worldwide’s first acquisition since Kohlberg’s 2023 buyout. Reports cited an approximate $500 million price tag, though Worldwide declined to confirm financial details. Catalyst chairman Nick Dyer will join Worldwide’s board, and CEO Nik Morton will enter the executive team. The transaction aims to expand Worldwide’s early‑phase oncology footprint and offer hybrid service models to clients.